3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
205
pembrolizumab
169
Pemetrexed
144
Cisplatin
126
Paclitaxel
78
durvalumab
75
osimertinib
70
Nivolumab
68
Docetaxel
66
Specimen Handling
64
atezolizumab
60
Magnetic Resonance Spectroscopy
54
Etoposide
47
Gemcitabine
46
Radiotherapy
45
Radiosurgery
40
130-nm albumin-bound paclitaxel
36
Drug Therapy
33
Bevacizumab
29
Cetuximab
28
Ipilimumab
27
cemiplimab
25
Taxes
24
tislelizumab
21
Immunoglobulin G
21
Radiation
20
Platinum
20
Biopsy
20
amivantamab
19
Disulfides
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Thoracic
×
90 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled